MX345953B - Usos de inmunoconjugados dirigidos a cd138. - Google Patents

Usos de inmunoconjugados dirigidos a cd138.

Info

Publication number
MX345953B
MX345953B MX2014008540A MX2014008540A MX345953B MX 345953 B MX345953 B MX 345953B MX 2014008540 A MX2014008540 A MX 2014008540A MX 2014008540 A MX2014008540 A MX 2014008540A MX 345953 B MX345953 B MX 345953B
Authority
MX
Mexico
Prior art keywords
targeting
immunoconjugates targeting
immunoconjugates
treatment
immunconjugates
Prior art date
Application number
MX2014008540A
Other languages
English (en)
Inventor
Schulz Gregor
Osterroth Frank
Haeder Thomas
Bruecher Christoph
Niemann Gabriele
Uherek Christoph
Daelken Benjamin
Wartenberg-Demand Andrea
Zuber Chantal
Engling André
Czeloth Niklas
Aigner Silke
Zeng Steffen
Original Assignee
Biotest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotest Ag filed Critical Biotest Ag
Publication of MX345953B publication Critical patent/MX345953B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un inmuconjugado para usarse en el tratamiento de un paciente con una enfermedad asociada con células blanco que expresan CD138, el inmunoconjugado comprende: al menos un anticuerpo dirigido que hace blanco en células que expresan CD138, y al menos una molécula efectora, en donde el anticuerpo dirigido se enlaza funcionalmente con la molécula efectora para formar el inmunoconjugado, en donde el anticuerpo dirigido comprende residuos aminoácidos 24-34, 50.56 y 89-97 de SEQ ID NO: 2, y comprende residuos de aminoácidos 31-35, 51-68 y 99-111 de SEQ ID NO: 1, en donde al menos una parte del anticuerpo dirigido confiere propiedades de isotipo IgG4, en donde al menos una molécula efectora es un maitansinoide, y en donde la enfermedad es un carcinoma mamario, que es receptor negativo de estrógeno, un receptor negativo progesterona y resistente a herceptina, o un carcinoma pancreático.
MX2014008540A 2009-05-06 2010-05-05 Usos de inmunoconjugados dirigidos a cd138. MX345953B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17606909P 2009-05-06 2009-05-06
US25943009P 2009-11-09 2009-11-09
PCT/EP2010/056124 WO2010128087A2 (en) 2009-05-06 2010-05-05 Uses of immunoconjugates targeting cd138

Publications (1)

Publication Number Publication Date
MX345953B true MX345953B (es) 2017-01-27

Family

ID=42752045

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014008540A MX345953B (es) 2009-05-06 2010-05-05 Usos de inmunoconjugados dirigidos a cd138.
MX2011011684A MX2011011684A (es) 2009-05-06 2010-05-05 Usos de inmunoconjugados dirigidos a cd138.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2011011684A MX2011011684A (es) 2009-05-06 2010-05-05 Usos de inmunoconjugados dirigidos a cd138.

Country Status (16)

Country Link
US (1) US9289509B2 (es)
EP (1) EP2427216B1 (es)
JP (2) JP2012526079A (es)
KR (1) KR101725170B1 (es)
CN (1) CN102573916B (es)
AU (1) AU2010244428B2 (es)
BR (1) BRPI1013990A2 (es)
CA (1) CA2761120A1 (es)
ES (1) ES2726022T3 (es)
IL (1) IL216166A0 (es)
MX (2) MX345953B (es)
NZ (2) NZ596807A (es)
RU (2) RU2561041C2 (es)
SG (2) SG10201401976YA (es)
WO (1) WO2010128087A2 (es)
ZA (1) ZA201108341B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2486285C (en) 2004-08-30 2017-03-07 Viktor S. Goldmakher Immunoconjugates targeting syndecan-1 expressing cells and use thereof
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
EP2200634B1 (en) 2007-09-21 2015-02-11 The Regents of The University of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
ES2543201T3 (es) * 2007-12-26 2015-08-17 Biotest Ag Métodos y agentes que mejoran la dirección a las células tumorales que expresan CD138
ES2526433T3 (es) * 2007-12-26 2015-01-12 Biotest Ag Inmunoconjugados dirigidos a CD138 y usos de los mismos
CA2710453C (en) 2007-12-26 2019-07-02 Biotest Ag Agents targeting cd138 and uses thereof
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
CA2858133A1 (en) * 2011-12-08 2013-06-13 Biotest Ag Uses of immunoconjugates targeting cd138
EP3388083A1 (en) * 2012-03-09 2018-10-17 Lankenau Institute for Medical Research Compositions and methods for treating cancer
JP5993093B2 (ja) 2012-10-12 2016-09-14 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン類およびその複合体
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
US9803021B2 (en) * 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
CA2896248A1 (en) * 2012-12-27 2014-07-03 Sanofi Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
NZ712035A (en) 2013-03-13 2019-06-28 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US20160022813A1 (en) * 2013-03-13 2016-01-28 Sanofi Compositions comprising anti-cd38 antibodies and carfilzomib
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
WO2015105995A2 (en) * 2014-01-08 2015-07-16 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
GB2526139A (en) * 2014-05-15 2015-11-18 Biolnvent Internat Ab Medicaments, uses and methods
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
US20160058884A1 (en) * 2014-09-02 2016-03-03 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US20200023072A1 (en) 2016-10-11 2020-01-23 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
KR102487144B1 (ko) 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 큰 물질의 경피 전달
CN110691793A (zh) * 2017-04-26 2020-01-14 田边三菱制药株式会社 黏结蛋白聚糖-1（cd138）结合剂及其用
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
CN111183157A (zh) 2017-10-02 2020-05-19 威特拉公司 Cd138抗体分子及其用途
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
AU2019272838A1 (en) 2018-05-23 2020-11-26 Adc Therapeutics Sa Molecular adjuvant
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
CN112279917B (zh) * 2020-06-01 2024-01-05 普众发现医药科技(上海)有限公司 可应用于肿瘤细胞捕获的小鼠抗细胞表面糖蛋白cd138的单克隆抗体
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2023019204A2 (en) * 2021-08-11 2023-02-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or characterizing hematological malignancies and precursor conditions
KR20230049463A (ko) * 2021-10-06 2023-04-13 주식회사 이뮤노로지컬디자이닝랩 Cd138을 인식하는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034223A (en) 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5612016A (en) 1988-04-01 1997-03-18 Immunomedics, Inc. Conjugates of antibodies and bifunctional ligands
US6080777A (en) 1992-01-31 2000-06-27 The Trustees Of Columbia University In The City Of New York Taxol as a radiation sensitizer
US6087362A (en) 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CA2427858A1 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
CA2838062C (en) 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AU2003234194A1 (en) 2002-04-23 2003-11-10 Meir Strahilevitz Methods and devices for targeting a site in a mammal and for removing species from a mammal
DE602004028337D1 (de) 2003-01-22 2010-09-09 Glycart Biotechnology Ag Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion
EP1627081A4 (en) 2003-05-02 2006-08-16 Health Research Inc USE OF JAG2 EXPRESSION IN THE DIAGNOSIS OF PLASMIC CELL DISORDERS
AU2004257142A1 (en) * 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
ATE496944T1 (de) 2003-07-21 2011-02-15 Immunogen Inc Ca6-antigenspezifisches zytotoxisches konjugat und verfahren zu dessen anwendung
CA2486285C (en) * 2004-08-30 2017-03-07 Viktor S. Goldmakher Immunoconjugates targeting syndecan-1 expressing cells and use thereof
CA2600065A1 (en) 2005-02-23 2006-10-12 Franck Amblard Honokiol derivatives for the treatment of proliferative disorders
CA2600712A1 (en) 2005-03-14 2006-09-21 Immunomedics, Inc. Methods of treating cancer using ppar-gamma antagonists
WO2006099875A1 (en) * 2005-03-23 2006-09-28 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
TW200738750A (en) * 2005-12-06 2007-10-16 Domantis Ltd Ligands and methods of use therefor
AR058983A1 (es) * 2006-01-13 2008-03-05 Irm Llc Metodos y composiciones para el tratamiento de enfermedades alergicas
WO2007144046A2 (de) 2006-05-03 2007-12-21 Elke Pogge Von Strandmann Mittel zur behandlung von malignen erkrankungen
CN104761641A (zh) * 2007-06-12 2015-07-08 Ac免疫有限公司 β淀粉样蛋白的人源化抗体
CA2694987A1 (en) 2007-07-17 2009-01-22 Combinatorx, Incorporated Combinations for the treatment of b-cell proliferative disorders
CA2710453C (en) 2007-12-26 2019-07-02 Biotest Ag Agents targeting cd138 and uses thereof
ES2526433T3 (es) 2007-12-26 2015-01-12 Biotest Ag Inmunoconjugados dirigidos a CD138 y usos de los mismos
ES2543201T3 (es) 2007-12-26 2015-08-17 Biotest Ag Métodos y agentes que mejoran la dirección a las células tumorales que expresan CD138
AR069979A1 (es) 2007-12-26 2010-03-03 Biotest Ag Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados
US8563700B2 (en) 2008-06-16 2013-10-22 Immunogen, Inc. Synergistic effects

Also Published As

Publication number Publication date
AU2010244428B2 (en) 2015-01-29
SG10201401976YA (en) 2014-10-30
ES2726022T3 (es) 2019-10-01
US20110123554A1 (en) 2011-05-26
NZ596807A (en) 2013-09-27
KR20120047209A (ko) 2012-05-11
RU2561041C2 (ru) 2015-08-20
RU2011149471A (ru) 2013-06-20
IL216166A0 (en) 2012-01-31
EP2427216A2 (en) 2012-03-14
ZA201108341B (en) 2019-07-31
CN102573916A (zh) 2012-07-11
CN102573916B (zh) 2017-05-17
EP2427216B1 (en) 2019-02-20
WO2010128087A2 (en) 2010-11-11
WO2010128087A9 (en) 2011-05-19
RU2015128833A3 (es) 2019-03-01
RU2015128833A (ru) 2015-11-10
WO2010128087A3 (en) 2011-01-27
NZ613647A (en) 2015-02-27
US9289509B2 (en) 2016-03-22
JP2012526079A (ja) 2012-10-25
SG175421A1 (en) 2011-12-29
JP6165213B2 (ja) 2017-07-19
AU2010244428A1 (en) 2011-12-15
MX2011011684A (es) 2012-01-20
CA2761120A1 (en) 2010-11-11
KR101725170B1 (ko) 2017-04-10
JP2016053053A (ja) 2016-04-14
BRPI1013990A2 (pt) 2019-04-30

Similar Documents

Publication Publication Date Title
MX345953B (es) Usos de inmunoconjugados dirigidos a cd138.
ZA202202711B (en) Sustained-release dosage forms of ruxolitinib
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
NZ720743A (en) Peptidomimetic compounds and antibody-drug conjugates thereof
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
MX2013006591A (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
JO3522B1 (ar) تركيب صيدلاني يتألف من كريات حمراء تغلف إنزيم يعتمد على بيريدكسال الفوسفات والعامل المساعد له
NZ720736A (en) Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
IN2012DN02805A (es)
IN2012DN06720A (es)
HK1140940A1 (en) Titration of tapentadol
MY186106A (en) Diagnosis, prevention and treatment of diseases of the joint
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
WO2012129112A3 (en) Use of intracellular enzymes for the release of covalently linked bioactives
IN2012DN02471A (es)
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
NZ702242A (en) Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent
NZ602145A (en) Ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
NZ604018A (en) Furanyl compounds and the use thereof
ES2325291A1 (es) "uso de un extracto de silybum marianum"
WO2013157889A9 (ko) 신규한 아미노피리딘 유도체의 암 예방 또는 치료 용도
TN2012000256A1 (en) Therapeutic use of protein-polymer conjugates
PH12019501070A1 (en) Sustained-release dosage forms of ruxolitinib